CP and cancer: Accordingly, it has been demonstrated that in HeLa cells overexpressing cyclin I, the activation of CDK5 by cyclin I confers cancer cell resistance to CP, while knockdown of CDK5 with siRNA significantly increases the sensitivity to CP [13].